MGRX:NASDAQ, Mangoceuticals, Inc.

MGRX stock overview

Mangoceuticals, Inc. (MGRX:NASDAQ) closed at $0.330 on October 15, 2026, up 0.73% on the day. The stock trades 88.0% below its 52-week high of $2.75 and 103.7% above its 52-week low of $0.162. Over the past year, it lost 87.1%. Mangoceuticals, Inc. is part of the Health Care sector.

Key figures

Price

$0.330

Day change

+0.73%

Volume

558,607

Average volume

12,814,667

Market cap

7M+

52-week range

$0.162 – $2.75

50-day average

$0.437

200-day average

$0.439

Performance

Price action over the past year

In 252 trading sessions since October 14, 2025, MGRX closed higher on 112 days (44%). Its best day was March 23, 2026 (+100.00%) and its worst was March 20, 2026 (-54.49%). The stock moved 10% or more in a single session 55 times. It opened at least 5% above the previous day's high 6 times.

Recent signals

• Oct 14, 2026: Down 31.4% over 14 days, from $0.481 (Dips & Crashes scanner)
• Oct 14, 2026: Hit a new 1-Month Low of $0.328 (New Highs/Lows scanner)
• Oct 1, 2026: News catalyst: Investor Update (News Catalysts scanner)
• Oct 1, 2026: Spiked to $0.520 on 2M+ shares (Spikes scanner)

MGRX news

• Oct 9, 2026: Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close
• Oct 1, 2026: Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche
• Aug 13, 2026: Mangoceuticals Inc.'s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets
• Aug 6, 2026: Mangoceuticals' Merger Partner, Nuclea Energy Inc., Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure
• Aug 5, 2026: Mangoceuticals' Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development
• Aug 5, 2026: Mangoceuticals' Merger Partner, Nuclea Energy ("Nuclea"), Executes MOU with Utah Office of Energy Development
• Aug 4, 2026: Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination
• Jul 30, 2026: Nuclea Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance the Morpheus Microreactor

About Mangoceuticals, Inc.

Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The platform provide access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED product.

Find more stocks like MGRX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.